Nanotechnology-empowered strategies in treatment of skin cancer
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
In current scenario skin cancer is a serious condition that has a significant impact on world health. Skin cancer is divided into two categories: melanoma skin cancer (MSC) and non-melanoma skin cancer (NMSC). Because of its significant psychosocial effects and need for significant investment in new technology and therapies, skin cancer is an illness of global health relevance. From the patient's perspective chemotherapy considered to be the most acceptable form of treatment. However, significant negatives of chemotherapy such as severe toxicities and drug resistance pose serious challenges to the treatment. The field of nanomedicine holds significant promise for enhancing the specificity of targeting neoplastic cells through the facilitation of targeted drug delivery to tumour cells. The integration of multiple therapeutic modalities to selectively address cancer-promoting or cell-maintaining pathways constitutes a fundamental aspect of cancer treatment. The use of mono-therapy remains prevalent in the treatment of various types of cancer, it is widely acknowledged in the academic community that this conventional approach is generally considered to be less efficacious compared to the combination treatment strategy. The employment of combination therapy in cancer treatment has become increasingly widespread due to its ability to produce synergistic anticancer effects, mitigate toxicity associated with drugs, and inhibit multi-drug resistance by means of diverse mechanisms. Nanotechnology based combination therapy represents a promising avenue for the development of efficacious therapies for skin cancer within the context of this endeavour. The objective of this article is to provide a description of distinct challenges for efficient delivery of drugs via skin. This article also provides a summary of the various nanotechnology based combinatorial therapy available for skin cancer with their recent advances. This review also focuses on current status of clinical trials of such therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Combination therapy in combating cancer
Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16723 · Cited by 2,543
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
D'Orazio, J., Jarrett, S., Amaro-Ortiz, A., & Scott, T. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140612222 · Cited by 1,984
Multi-target therapeutics: when the whole is greater than the sum of the parts
Zimmermann, G. R., Lehár, J., & Keith, C. T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.11.008 · Cited by 1,105
Gloster, H. M., & Neal, K. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.08.063 · Cited by 668
Biomedical applications of nisin
Shin, J. M., Gwak, J. W., Kamarajan, P., Fenno, J. C., Rickard, A. H., & Kapila, Y. L. (2016) · Journal of Applied Microbiology · doi:10.1111/jam.13033 · Cited by 607
Nanomedicine of synergistic drug combinations for cancer therapy – Strategies and perspectives
Zhang, R. X., Wong, H. L., Xue, H. Y., Eoh, J. Y., & Wu, X. Y. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.012 · Cited by 380
Organ-on-a-Chip for Cancer and Immune Organs Modeling
Sun, W., Luo, Z., Lee, J., Kim, H., Lee, K., Tebon, P., Feng, Y., Dokmeci, M. R., Sengupta, S., & Khademhosseini, A. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801363 · Cited by 221
Cited by
Hasan, N., Nadaf, A., Imran, M., Jiba, U., Sheikh, A., Almalki, W. H., Almujri, S. S., Mohammed, Y. H., Kesharwani, P., & Ahmad, F. J. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01854-3 · Cited by 322
Self-citationZhang, Y., Wang, Z., Wang, Y., Jin, W., Zhang, Z., Jin, L., Qian, J., & Zheng, L. (2024) · PeerJ · doi:10.7717/peerj.18636 · Cited by 127
De, A., Mishra, N., & Chang, H.-T. (2024) · PeerJ Computer Science · doi:10.7717/peerj-cs.1884 · Cited by 42
Ahammed, S., Cui, X., Lu, W., & Yap, M. H. (2025) · 2025 IEEE/CVF Conference on Computer Vision and Pattern Recognition Workshops (CVPRW) · doi:10.1109/cvprw67362.2025.00027 · Cited by 12
“Skin cancer is the most widespread cancer globally, with its continuously increasing and is the fifth most common form of cancer [4, 7, 19].”
Metadata
- Authors
- Chandra, J., Hasan, N., Nasir, N., Wahab, S., Thanikachalam, P. V., Sahebkar, A., Ahmad, F. J., & Kesharwani, P.
- Venue
- Environmental Research
- Publisher
- Elsevier BV
- Published
- 2023-10
- Volume
- 235
- Pages
- 116649
- ISSN
- 0013-9351 (ISSN-L)
- OpenAlex
- W4384023705
- Cited by
- 76
- References
- 12
- FWCI
- 6.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nanotechnology-empowered strategies in treatment of skin cancer. https://app.cochat.ai/papers/10.1016/j.envres.2023.116649
- The paper
- Chandra, J., Hasan, N., Nasir, N., Wahab, S., Thanikachalam, P. V., Sahebkar, A., Ahmad, F. J., & Kesharwani, P. (2023). Nanotechnology-empowered strategies in treatment of skin cancer. Environmental Research. https://doi.org/10.1016/j.envres.2023.116649
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.